Dr. Melear is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11111 Research Blvd
Suite 400
Austin, TX 78759Phone+1 512-419-9733Fax+1 512-349-0406
Education & Training
Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2001- Baylor University Medical CenterResidency, Internal Medicine, 1996 - 1999
Texas Tech University Health Sciences Center School of MedicineClass of 1996
Certifications & Licensure
TX State Medical License 1997 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Super Doctor SuperDoctors.com
Clinical Trials
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Start of enrollment: 2018 Oct 29
- Join now to see all
Publications & Presentations
PubMed
- 12 citationsDose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi
Nature Communications. 2023-07-24 - 53 citationsDaratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA studyHabte A. Yimer, Jason M. Melear, Edward A. Faber, William I. Bensinger, John M. Burke
British Journal of Haematology. 2019-05-01 - 9 citationsDaratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke
Leukemia & Lymphoma. 2022-10-01
Abstracts/Posters
- Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezom...Jason M. Melear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b StudyJason M. Melear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Blood Cancer Breakthroughs with Dr. Jason MelearFebruary 25th, 2020- Blood Cancer Breakthroughs: Targeted Therapies Take the Lead in the Future of TreatmentFebruary 1st, 2020
- The Benefits and Risks to Consider in Clinical TrialsMay 18th, 2018
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
